戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 teasome inhibitor MG132 and a Cullin5 (Cul5) dominant negative mutant.
2 d 293 cells stably expressing the PERK-K618A dominant negative mutant.
3  allele expressed, although not as a classic dominant-negative mutant.
4 steoclastogenesis was also inhibited by Dvl2 dominant negative mutants.
5 small) G-proteins yield nucleotide-depleted, dominant-negative mutants.
6 , and JNK were assessed using inhibitors and dominant-negative mutants.
7 n lesions, and we also examine phenotypes of dominant-negative mutants.
8 LN3 function by expression of a channel-dead dominant negative mutant (458DD/KK) or by knockdown of e
9 ion; however, inactivating SHP2 and p38 with dominant negative mutants abrogated CXCL8 induction.
10 f that PI3K by either chemical inhibitors or dominant-negative mutants abrogated the inhibitory effec
11 ase and Akt by either chemical inhibitors or dominant-negative mutants abrogated the RNS60-mediated u
12 a-arrestin using either siRNA knockdown or a dominant negative mutant abrogates the enhanced CXCL12-d
13 and Cdc42 using pharmacologic inhibitors and dominant negative mutants also inhibited the fMLF-induce
14 1b and ZmETR2b that is present in the etr1-1 dominant negative mutant and expressed each protein in A
15                                        Using dominant negative mutants and rescue experiments, we dem
16 -Cys (DHHC) zinc finger protein; (ii) a GODZ dominant-negative mutant and an inhibitor of palmitoylat
17                   Kinase-dead PRK2 acts as a dominant-negative mutant and prevents apical junction fo
18                        In contrast, both the dominant-negative mutant and the phosphoinositide lipids
19 ereas AP-1 activation decreased in both MSK1 dominant-negative mutants and in MSK1 knockdown cells.
20 ection of IL-6 promoter reporter constructs, dominant negative mutants, and electromobility shift ass
21                      Using inhibitory drugs, dominant negative mutants, and small interfering RNAs (s
22           Here we establish, using shRNAs, a dominant-negative mutant, and a pharmacologic inhibitor,
23      Inhibition of MEK1 by pharmacologic and dominant-negative mutant approaches attenuated 15(S)-HET
24 ockade of Egr-1 via forced expression of its dominant-negative mutant attenuated 15(S)-HETE-induced H
25 on via adenovirus-mediated expression of its dominant-negative mutant attenuated 15(S)-HETE-induced H
26 EB activation by pharmacologic inhibition or dominant negative mutants blocks the 5-LO-dependent elev
27 p1 activation by pharmacologic inhibition or dominant-negative mutant blocks the 12/15-LO-dependent e
28 holinos or a naturally occurring human BMP15 dominant-negative mutant (BMP15-Y235C) leads to embryos
29                                          Syk dominant negative mutant but not epidermal growth factor
30 red in the basilar artery of mice expressing dominant-negative mutants, but not in mice expressing wi
31 erestingly, overexpression of the Ubc9 trans-dominant-negative mutant C93A, which is a defective E2-S
32 yonic fibroblasts (MEFs) and overexpressed a dominant-negative mutant CKIepsilon (DN-CKIepsilon) in t
33                     Moreover, CUL2 and UBE2M dominant negative mutants competitively inhibited the BI
34  Knockdown of Arkadia or overexpression of a dominant-negative mutant completely abolishes transcript
35  Jam-B and Jam-C using antibodies, siRNA, or dominant-negative mutants completely interferes with lum
36 ng beta-catenin signaling by transfection of dominant-negative mutant constructs to either T-cell fac
37 -type CREB promoted SnoN expression, whereas dominant negative mutant CREB abrogated SnoN induction b
38 ression of GDP-locked Rab4S22N and Rab11S25N dominant-negative mutants decreased the steady-state Kv1
39                         BAF57 RNAi and BAF57 dominant negative mutants defective in CaM binding simil
40                             Moreover, a rio1 dominant-negative mutant defective in ATP hydrolysis ind
41        Disruption of IRF8 function with IRF8 dominant-negative mutants diminished Fas-mediated apopto
42 dialysis and molecular biology in a putative dominant-negative mutant DISC1 transgenic model.
43 ochondrial fission through expression of the dominant-negative mutant DLP1-K38A eliminated this dynam
44 t, MSK1 COOH terminal or NH(2) terminal dead dominant negative mutants dramatically suppressed cell t
45 of TSHR internalization, and expression of a dominant-negative mutant dynamin, which inhibited intern
46 elta-small interfering RNA, or with PKCdelta dominant-negative mutant effectively increased a number
47               Blocking TCF-4 activity with a dominant-negative mutant enhanced HIV replication by thr
48                       Stable expression of a dominant-negative mutant ERK eliminated the effects of i
49 riggered by canonical Wnt ligands, LRP6, and dominant negative mutants for Axin and GSK3, indicating
50 orrected by intramuscular gene transfer of a dominant negative mutant form of p75(NTR).
51 n muscle-specific transgenic mice expressing dominant-negative mutant form of AMPK or in AdipoR1-knoc
52 not its mutant, or ectopic expression of the dominant-negative mutant form of ATF-6 protected cells f
53 teins mitofusin 1 or 2 or with Drp1(K38A), a dominant-negative mutant form of Drp1, increased the per
54      By using cell lines stably expressing a dominant-negative mutant form of VPS4, we also show that
55 /2, and mitochondrial complex II; as well as dominant negative mutant forms of IkappaBalpha and NOX4
56 the role of Sar1p in pexophagy by expressing dominant-negative mutant forms of Sar1p in Pichia pastor
57                                      We used dominant negative mutant, genetic knockout, gene knockdo
58                      Overexpression of STAT3 dominant-negative mutants greatly diminishes this SOCS-3
59 R2 using an inhibitor, short hairpin RNA and dominant-negative mutant HER2 abolished IR-induced activ
60 nfected with GFP (control), hERG (I(Kr)), or dominant negative mutant hERG G628S.
61                                Expression of dominant negative mutant HNF-1beta or kidney-specific in
62  SOCS-3 in renal epithelial cells expressing dominant-negative mutant HNF-1beta rescues the defect in
63 ice and in renal epithelial cells expressing dominant-negative mutant HNF-1beta.
64 t mice and renal epithelial cells expressing dominant-negative mutant HNF-1beta.
65                                            A dominant-negative mutant, HRES-1/Rab4(S27N) had reduced
66 ith endothelium-targeted overexpression of a dominant-negative mutant human insulin receptor (ESMIRO)
67 ng B16/OVA cells engineered to overexpress a dominant negative mutant IFN-gamma receptor (B16/OVA/DNM
68 e to IFN-gamma" (MIIG) mice, which express a dominant negative mutant IFN-gamma receptor in CD68+ cel
69 ce showed that the CDK2-DN protein acts as a dominant negative mutant in mature T cells as expected,
70 d how CHIP recognizes Hsp/c70, we utilized a dominant negative mutant in which loss of a conserved pr
71 terfering with BVES function by expressing a dominant-negative mutant in human corneal epithelial cel
72 on via gene silencing or overexpression of a dominant negative mutant increased human keratinocyte ce
73         Conversely, overexpression of a STX6 dominant-negative mutant increases CFTR.
74 ting recruitment of Vinculin by expressing a dominant-negative mutant increases the rate of furrow in
75                        Coro1A(E26K) is not a dominant-negative mutant, indicating that its pathologic
76  knockdown of alphaSNAP or expression of its dominant negative mutant induced epithelial cell apoptos
77 n of PKMzeta in mPFC by expressing a PKMzeta dominant-negative mutant induced depressive-like behavio
78 own, knock-out, and enforced expression of a dominant-negative mutant inhibited rictor ubiquitination
79 ase-defective DHX33 mutant (K94R) acted as a dominant negative mutant, inhibiting endogenous rRNA syn
80 aB-specific inhibitor or overexpression of a dominant negative mutant inhibitory NF-kappaB (IkappaBal
81                       Blockade of ATR with a dominant-negative mutant inhibits cisplatin-induced p53
82  was severely impaired in cells expressing a dominant-negative mutant IRF3 and completely abrogated i
83 induced by Sgo1 depletion or expression of a dominant negative mutant is suppressed by ectopic expres
84                                  Analysis of dominant negative mutants is consistent with dimerizatio
85 g a missense R174Q mutation, which acts as a dominant-negative mutant, is associated with thrombocyto
86 ediated engulfment, we used a combination of dominant-negative mutants, knockdown of specific signali
87 , we overexpressed beta-arrestin2-(1-320), a dominant negative mutant known to block receptor endocyt
88 lize with GPER, and expression of arrestin-2 dominant-negative mutants lacking clathrin- or beta-adap
89 -positive (LdRab5a:Q93L and LdRab5b:Q80L) or dominant-negative mutants (LdRab5a:N146I and LdRab5b:N13
90  small interfering RNA or by expression of a dominant negative mutant led to inhibition of wound-indu
91        The second, trlR, is a nonfunctional, dominant-negative mutant located in an operon that is in
92 NFAT-dependent manner and pharmacological or dominant negative mutant-mediated blockade of PKN1 funct
93                                              Dominant negative mutant-mediated interference of RhoA a
94                                              Dominant-negative mutant-mediated interference of STAT-5
95            Using Rac1-specific inhibitor and dominant-negative mutant N17Rac1, here we demonstrate th
96 heavy chain depletion or expression of AP180 dominant-negative mutant not only disrupted clathrin-reg
97 B1 was abrogated by the co-transduction of a dominant negative mutant of AMPK.
98 Kalpha1 subunit, whereas the expression of a dominant negative mutant of AMPKalpha1 or ablation of AM
99 ll proliferation as does overexpression of a dominant negative mutant of BAP1.
100 harmacological inhibitor and expression of a dominant negative mutant of c-Abl, we show an essential
101 firmed by conditional expression of TAM67, a dominant negative mutant of cJun.
102   CRAG knockdown by siRNA or expression of a dominant negative mutant of CRAG significantly attenuate
103 f HeLa cells with MLN4924 or expression of a dominant negative mutant of cullin1 inhibited the Vpu-me
104 ace OAT1 increases in cells transfected with dominant negative mutant of dynamin-2, a maneuver blocki
105                          Overexpression of a dominant negative mutant of EhRab35 reduced phagocytic c
106 r pathways due to transgenic expression of a dominant negative mutant of Fas-associated death domain
107            In addition, we have identified a dominant negative mutant of GAPDH, which inhibits RNA sy
108 rotein expression, while the expression of a dominant negative mutant of GATA-3 or a GATA-3 shRNA con
109        Here we report that overexpression of dominant negative mutant of GRK5 (dnGRK5) in a cholinerg
110 unoprecipitated with wild-type Hsc70, with a dominant negative mutant of Hsc70, and with the minimal
111 ith cardiomyocyte-restricted expression of a dominant negative mutant of IkappaBalpha (IkappaBalpha(S
112 o induce NRF2 because either expression of a dominant negative mutant of IkappaBalpha that leads to N
113                                    Indeed, a dominant negative mutant of KCNQ4_v1 cripples the curren
114 ylation of p38, and that overexpression of a dominant negative mutant of MKP-1 does the opposite.
115            Selective knockdown of MyD88 by a dominant negative mutant of MyD88 or selective siRNA als
116  and functional role of omega, we isolated a dominant negative mutant of omega (omega6), which is pre
117                              Expression of a dominant negative mutant of p53 causes significant rever
118 horylation of PKCzeta can be suppressed by a dominant negative mutant of PDK1.
119  down- or up-regulated in cells expressing a dominant negative mutant of Pdx-1.
120 lly, EEA1 down-regulation or expression of a dominant negative mutant of PKC-alpha blunts Ang II-indu
121  of Rab1), and GFP-LdRab1:S22N (a GDP-locked dominant negative mutant of Rab1).
122 f rLCMV-LASVGP was only mildly affected by a dominant negative mutant of Rab5 and was independent of
123                                            A dominant negative mutant of Rac1 abolished tRA-induced p
124 ated gene transfer, that overexpression of a dominant negative mutant of Rac1 or local knockout of Ra
125                               The use of the dominant negative mutant of Ras has been crucial in eluc
126                                  Moreover, a dominant negative mutant of SCG10 (Cys 22,Cys 24-->Ala 2
127 mic reticulum-derived vesicle formation by a dominant negative mutant of small GTPase Sar1 had no det
128             Furthermore, overexpression of a dominant negative mutant of TAK1 blocked the TNF-alpha-i
129                          Overexpression of a dominant negative mutant of TAK1 or knockdown of TAK1 in
130 n of cyt b(558), which could be blocked by a dominant negative mutant of the clathrin-coated pit-asso
131 iving adenovirus that encoded KCNH2-G628S, a dominant negative mutant of the I(Kr) potassium channel
132                              Expression of a dominant negative mutant of these factors in transgenic
133               Transfection of cells with the dominant negative mutant of ubiquitin Ub-K48R, which pre
134 ited by the proteasome inhibitor MG132 and a dominant negative mutant of ubiquitin, K6W-Ub, indicatin
135 express wild-type, constitutively active, or dominant negative mutant of various Rab GTPases.
136 ag-ESCRT-I or -II fusions was inhibited by a dominant negative mutant of Vps4 ATPase similar to wild
137 same way as did reduced ARAP2 expression and dominant negative mutants of Arf6 and Rac1 reversed the
138  and identified constitutively activated and dominant negative mutants of DLC-1.
139 n of K(+) from the cells, or transfection of dominant negative mutants of dynamin-2 or Eps15 into the
140 R2, and ERS2, are present in Arabidopsis and dominant negative mutants of each that confer ethylene i
141 , while inhibiting Cdc42 signaling by either dominant negative mutants of FGD1 or Cdc42 suppressed os
142 is stimulated by FLASH and inhibited by both dominant negative mutants of FLASH and anti-FLASH antibo
143                      Furthermore, the use of dominant negative mutants of histone H3 revealed that Co
144                       We further showed that dominant negative mutants of Hsc70 were also recruited t
145   However, Dynasore (dynamin inhibitor), the dominant negative mutants of NM23-H1 (dynamin activator)
146 on and was reduced in cells transfected with dominant negative mutants of p115-Rho GEF or RhoA, and b
147 ologs in a yeast model host or expression of dominant negative mutants of plant Rab5 greatly decrease
148 ficient or phosphorylation-defective (Y402F) dominant negative mutants of Pyk2.
149 hanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek
150                        The identification of dominant negative mutants of Vif presents exciting possi
151                 In this study, we identified dominant negative mutants of Vif that interfered with th
152 terfering RNA, an AKT inhibitor as well as a dominant-negative mutant of AKT1, blocks this activation
153 st SB431542 and overexpression of Smad7 or a dominant-negative mutant of Alk-5.
154 tablished stable cell lines by introducing a dominant-negative mutant of AMPK alpha1 subunit or its s
155 brogated by small hairpin RNA (shRNA) or the dominant-negative mutant of AMPK alpha1 subunit.
156 ological inhibition of AMPK, expression of a dominant-negative mutant of AMPKalpha1, and P2Y receptor
157         Expression of a ceramide-binding but dominant-negative mutant of aPKC suppresses ciliogenesis
158 2 target gene expression via expression of a dominant-negative mutant of ATF2 or expression of an ATF
159                         In the presence of a dominant-negative mutant of beta-actin, the repositionin
160 e is shortened by betaTrCP but extended by a dominant-negative mutant of betaTrCP, by RSK1/S6K1 inhib
161 B) activation] or overexpression of TAM67 (a dominant-negative mutant of c-Jun) dramatically inhibite
162 e also found in transgenic mice expressing a dominant-negative mutant of Cadm4 lacking its cytoplasmi
163             In addition, overexpression of a dominant-negative mutant of caveolin 1 did not have any
164                                   By using a dominant-negative mutant of Cul5 and silencing Cul5 expr
165 p junction coupling by viral expression of a dominant-negative mutant of Cx26 (also known as Gjb2) or
166       Inhibition of DNM2 GTPase activity and dominant-negative mutant of DNM2 showed a functional rol
167 iral-mediated gene transfer to overexpress a dominant-negative mutant of DVL in NAc, or by using a ph
168 pressor of IkappaBalpha, or FAK, and using a dominant-negative mutant of FAK (FRNK), blocks melanoma
169                                Expression of dominant-negative mutant of Fas-associated death domain
170 h decreased cell viability in MDM, whereas a dominant-negative mutant of FOXO3a or small interfering
171  GSK3beta in the NAc, while overexpressing a dominant-negative mutant of GSK3beta promoted resilience
172 c mice with cardiac-specific expression of a dominant-negative mutant of IkappaB alpha (IkappaB alpha
173 arkedly impaired in C2C12 cells expressing a dominant-negative mutant of IkappaBalpha.
174                                     ANK, the dominant-negative mutant of ILK, also blocked the phosph
175 to express either a constitutively active or dominant-negative mutant of Inhibitor of kappa B kinase
176 g, which could be rescued by expression of a dominant-negative mutant of Lef1 that interferes with be
177 cretase inhibitor (GSI) or transduction of a dominant-negative mutant of MAML1.
178                            Transfection of a dominant-negative mutant of MEF2C significantly inhibite
179                                 Expressing a dominant-negative mutant of NF-YA, a key transcriptional
180 ly, NRF2 overexpression inhibited, whereas a dominant-negative mutant of NRF2 exacerbated RAC1-depend
181                               Accordingly, a dominant-negative mutant of p21(rac), but not p21(ras),
182  activation of NF-kappaB by Deltap21(ras), a dominant-negative mutant of p21(ras), supported the invo
183 specific expression of Pim-1 (Pim-WT) or the dominant-negative mutant of Pim-1 (Pim-DN) in transgenic
184                                  Moreover, a dominant-negative mutant of PKC-delta blocked albumin-in
185 eplication-deficient adenovirus expressing a dominant-negative mutant of protein kinase B (Akt) compa
186 urther confirmed by the forced expression of dominant-negative mutant of protein kinase C delta.
187               This effect was inhibited by a dominant-negative mutant of Rab11, suggesting that CIN85
188                                            A dominant-negative mutant of Rab8a strongly binds to the
189  and NF-kappaB, as well as transfection of a dominant-negative mutant of Ras (RasN17), significantly
190 differentiation by targeting expression of a dominant-negative mutant of retinoic acid receptor alpha
191                                            A dominant-negative mutant of RhoA also blocked U46619-ind
192 se observations suggest that D477G acts as a dominant-negative mutant of RPE65 that delays chromophor
193 r N',N'-dimethylsphingosine or expression of dominant-negative mutant of SK1(G82D) or specific small
194                          Overexpression of a dominant-negative mutant of SNX17 and RNA interference k
195  addition, adenovirus-mediated expression of dominant-negative mutant of Src blocked 15(S)-HETE's eff
196 nt for the transformation process, because a dominant-negative mutant of Stat3 interferes with PI3K-i
197 n the transcriptional level, expression of a dominant-negative mutant of the basic region leucine zip
198 hageal adenocarcinoma cells of beta2SP and a dominant-negative mutant of the Notch coactivator master
199 f30-depleted cells or cells overexpressing a dominant-negative mutant of the protein results from abe
200 th cone morphology, expression of a putative dominant-negative mutant of the receptor, CS-HmLAR2, lea
201                     Moreover, we show that a dominant-negative mutant of the ternary complex factor (
202    Consistent with this effect, expressing a dominant-negative mutant of ULK1 or ATG4b or a ULK1-targ
203  the erythroid cell-specific expression of a dominant-negative mutant of USF, A-USF, in transgenic mi
204                                 In contrast, dominant-negative mutants of Akt and pharmacologic inhib
205                    Constitutively active and dominant-negative mutants of AMPK and Akt were used to e
206                           Here, we show that dominant-negative mutants of ATL1 in PC-12 cells inhibit
207                                       First, dominant-negative mutants of CNOT7 and CNOT8 reduced PUM
208                                        Using dominant-negative mutants of dynamin-2 (dyn2K44A) and ca
209                                 Furthermore, dominant-negative mutants of either Cullin1 or Cullin5,
210 rmed by the expression of well-characterized dominant-negative mutants of genes in this pathway and b
211                              Coexpression of dominant-negative mutants of IkappaB kinase alpha (IKKal
212 atory effect was inhibited, however, by both dominant-negative mutants of Mek2 (Mek2-K101A) and K-Ras
213             In cultured hippocampal neurons, dominant-negative mutants of NPRAP designed to disrupt t
214                  We reported previously that dominant-negative mutants of one of the telomeric protei
215                                              Dominant-negative mutants of PAX5 and IKZF1, however, re
216                                              Dominant-negative mutants of PKC, short interfering RNA
217 elial function in transgenic mice expressing dominant-negative mutants of PPARgamma under the control
218                                          The dominant-negative mutants of RhoA and RhoC, but not Rac1
219                                 In contrast, dominant-negative mutants of SPTLC1 inhibited ABCA1 effl
220  generally cause pro-[PSI(+)] effects, since dominant-negative mutants of Ssa1 or Ssa2 cure [PSI(+)],
221 ology and Golgi movement through analyses of dominant-negative mutants of the putative GTPase domain
222                       Expression of specific dominant-negative mutants of the Xenopus Kir6.1 pore sub
223 on of TNF-induced superoxide generation with dominant-negative mutants of TRADD or Rac1, as well as k
224 ignificance of signaling was confirmed using dominant negative mutants or pharmacological inhibitors.
225  and were prevented by TRPC1, -C4, and Orai1 dominant negative mutants or TRPC5 siRNA.
226              Inhibition of TRF2, either by a dominant-negative mutant or by RNA interference, dissoci
227 eorganization of VIFs caused by expressing a dominant-negative mutant or by silencing vimentin with s
228 When vimentin organization is disrupted by a dominant-negative mutant or by silencing, there is a los
229 kyrin G function either by over-expressing a dominant-negative mutant or by siRNA knockdown decreases
230                  Inhibition of PKCdelta by a dominant-negative mutant or by targeted gene deletion bl
231 hibiting endogenous chaperone molecules by a dominant-negative mutant or chemical inhibitors recapitu
232   Inactivation of HIF by expression of a HIF dominant-negative mutant or deletion of HIF-1alpha by RN
233 ion of Merlin transport by expression of the dominant-negative mutant or depletion of kinesin-1 resul
234                      Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates c
235 cells, we show that FOXO1 inhibition using a dominant-negative mutant or lentivirus-encoded small hai
236 ical conditions in vivo, blocking it using a dominant-negative mutant or lithium chloride prevented m
237 nduced phosphorylation was abolished in MSK1 dominant-negative mutant or MSK1 knockdown cells.
238  interaction of UL20 with GODZ, using a GODZ dominant-negative mutant or possibly GODZ shRNA, should
239  cilia and inhibition of Rab11 function by a dominant-negative mutant or RNA interference blocks prim
240 ession of endogenous beta-TrCP function by a dominant-negative mutant or small interfering RNA-mediat
241               Disruption of RalA function by dominant-negative mutants or siRNA-mediated knockdown at
242 of Src, PLD1, or PKCgamma via pharmacologic, dominant negative mutant, or siRNA approaches significan
243               Inhibition of PLD2 by shRNA, a dominant-negative mutant, or a small molecule inhibitor
244 ession of a Gbetagamma sequestrant, a GRK2/3 dominant-negative mutant, or siRNA-mediated knockdown in
245 periments using PTP1B(-/-) fibroblast lines, dominant-negative mutants, or small interfering RNAs ind
246 1 shRNA (DPSC/ORAI1sh) or overexpressed with dominant negative mutant ORAI1(E106Q) (DPSC/E106Q) exhib
247 sed on the effects of expression of either a dominant-negative mutant Orai3 that is an essential comp
248                    Moreover, expression of a dominant-negative mutant Orai3, either alone or in cells
249                                          The dominant negative mutant ORF50DeltaSTAD requires the LR
250 en, California) gene switch technology and a dominant-negative mutant polypeptide of herpes simplex v
251                                   Also, this dominant negative mutant prevented accumulation of CerS6
252                                      Using a dominant-negative mutant protein of the methyl-directed
253               The expression of Rab20 or the dominant-negative mutant Rab20T19N does not affect trans
254 tively active Rab8, and coexpression of this dominant-negative mutant Rab8 blocks trafficking to the
255                            Expression of the dominant-negative mutant Rac1N17 inhibits the cortical F
256 versely, inhibition of STAT3 using siRNAs or dominant negative mutants reduced KIM-1 expression in a
257 levels of Cdc42-GTP, transfection of a Cdc42 dominant-negative mutant reduced cell growth and migrati
258 er-luciferase reporter constructs, whereas a dominant-negative mutant reduces expression.
259 state that can be induced by the presence of dominant-negative mutant repressors (Vir).
260          Depletion of Cep97 or expression of dominant-negative mutants results in CP110 disappearance
261 ls through RNA interference or expression of dominant-negative mutants results in differentiation.
262 olerance in HSFA6b-null, overexpression, and dominant negative mutants revealed that HSFA6b is a posi
263  phosphorylation and was reduced by the RhoA dominant negative mutant RhoA(T19N) and Rho and myosin l
264  smooth muscle contraction by expressing the dominant negative mutants RhoA T19N and cdc42 T17N, and
265 lls expressing either wild-type RNase L or a dominant-negative mutant RNase L were used to examine th
266 -mediated apoptotic cascade with a caspase-8 dominant-negative mutant significantly blocked sorafenib
267 ion by adenovirus-mediated expression of its dominant negative mutant, significantly attenuated 14,15
268 e inhibition of endogenous H-Ras by specific dominant-negative mutant/siRNA markedly ablated the HO-1
269 rsely regulated by NF2, through the use of a dominant-negative mutant, small hairpin RNA or a small m
270 orced expression of constitutively active or dominant-negative mutant STAT5A in mouse brain ECs, we f
271             Using protein kinase inhibitors, dominant negative mutant studies and mouse embryonic fib
272 on via adenovirus-mediated expression of its dominant-negative mutant suppressed 15(S)-HETE-induced H
273 r blocking their signaling by overexpressing dominant negative mutants suppresses netrin-1-induced gr
274  pseudosubstrate inhibitor, or its siRNA, or dominant negative mutants suppresses the cross-desensiti
275                      Moreover, expression of dominant-negative mutant Syt1 which inhibits Ca(2+)-depe
276 and elevated thyroid hormone levels due to a dominant-negative mutant T(3) receptor (TRbeta(PV)) that
277  inactivation of Cdc42 by overexpressing its dominant-negative mutant T17N in Sertoli cell epithelium
278 tive form of the cJun proto-oncogene, a cJun dominant negative mutant (Tam67), blocks AP-1 transcript
279 ling assay, we showed that the expression of dominant-negative mutant TAp73 expression plasmid (p73DD
280                                              Dominant-negative mutants targeting p38alpha and p38beta
281                Transgenic mice harboring the dominant-negative mutant TGF-beta type II receptor (DNTG
282 2 mutations detected so far are recessive, a dominant negative mutant that affects GlyT2 trafficking
283                      MLL fusions function as dominant negative mutants that abrogate the ATR-mediated
284                            Mice harbouring a dominant-negative mutant thyroid hormone receptor beta (
285                             Mice harboring a dominant-negative mutant thyroid hormone receptor-beta (
286  interfering RNA (siRNA) duplexes and ac-Cbl dominant negative mutant to show that c-Cbl is critical
287 pecific for Sdc1 and Sdc4 recognition act as dominant negative mutants to block cell spreading or cel
288 TEN lipid and protein phosphatase may act as dominant-negative mutants to suppress endogenous PTEN an
289 s TTP and BRF proteins, or overexpression of dominant-negative mutant TTP proteins, impairs the local
290                            Surprisingly, the dominant negative mutant Ubc9 (Ubc9-DN) also causes the
291 ession of UBE2L3 and LUBAC, but abolished by dominant-negative mutant UBE2L3 (C86S), or UBE2L3 silenc
292                 Like the previously isolated dominant-negative mutants, unc-108 loss-of-function muta
293 gether with pharmacological agents, RNAi and dominant negative mutants, we have demonstrated that tar
294 acological inhibitors, RNA interference, and dominant-negative mutants, we define the mechanisms invo
295                         Using inhibitors and dominant-negative mutants, we found that eIF4A is requir
296                        Short hairpin RNA and dominant-negative mutants were used to inhibit activitie
297                        Short hairpin RNA and dominant-negative mutants were used to inhibit activity
298                                         This dominant-negative mutant, which is deficient in GTP bind
299                              TRalpha1PV is a dominant negative mutant with a frameshift mutation in t
300 eversed by activated AKT and reproduced by a dominant negative mutant, wortmannin, or PTEN.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top